305 related articles for article (PubMed ID: 18676016)
1. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.
Tardi P; Johnstone S; Harasym N; Xie S; Harasym T; Zisman N; Harvie P; Bermudes D; Mayer L
Leuk Res; 2009 Jan; 33(1):129-39. PubMed ID: 18676016
[TBL] [Abstract][Full Text] [Related]
2. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.
Lim WS; Tardi PG; Dos Santos N; Xie X; Fan M; Liboiron BD; Huang X; Harasym TO; Bermudes D; Mayer LD
Leuk Res; 2010 Sep; 34(9):1214-23. PubMed ID: 20138667
[TBL] [Abstract][Full Text] [Related]
3. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse.
Bayne WF; Mayer LD; Swenson CE
J Pharm Sci; 2009 Jul; 98(7):2540-8. PubMed ID: 19009594
[TBL] [Abstract][Full Text] [Related]
5. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
Mayer LD; Tardi P; Louie AC
Int J Nanomedicine; 2019; 14():3819-3830. PubMed ID: 31213803
[TBL] [Abstract][Full Text] [Related]
6. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin.
Dicko A; Kwak S; Frazier AA; Mayer LD; Liboiron BD
Int J Pharm; 2010 May; 391(1-2):248-59. PubMed ID: 20156541
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells.
Gu C; Ye T; Wells RA
Leuk Res; 2006 Nov; 30(11):1447-51. PubMed ID: 16704876
[TBL] [Abstract][Full Text] [Related]
8. Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts.
Lim WS; Tardi PG; Xie X; Fan M; Huang R; Ciofani T; Harasym TO; Mayer LD
Leuk Lymphoma; 2010 Aug; 51(8):1536-42. PubMed ID: 20528246
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.
Carol H; Fan MM; Harasym TO; Boehm I; Mayer LD; Houghton P; Smith MA; Lock RB
Pediatr Blood Cancer; 2015 Jan; 62(1):65-71. PubMed ID: 25203866
[TBL] [Abstract][Full Text] [Related]
10. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
Cafaro A; Giannini MB; Silimbani P; Cangini D; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):455-466. PubMed ID: 32955826
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia.
Feldman EJ; Kolitz JE; Trang JM; Liboiron BD; Swenson CE; Chiarella MT; Mayer LD; Louie AC; Lancet JE
Leuk Res; 2012 Oct; 36(10):1283-9. PubMed ID: 22840315
[TBL] [Abstract][Full Text] [Related]
12. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals.
Ying X; Wen H; Lu WL; Du J; Guo J; Tian W; Men Y; Zhang Y; Li RJ; Yang TY; Shang DW; Lou JN; Zhang LR; Zhang Q
J Control Release; 2010 Jan; 141(2):183-92. PubMed ID: 19799948
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system.
Kishi S; Goto N; Nakamura T; Ueda T
Cancer Res; 1999 Jun; 59(11):2629-34. PubMed ID: 10363985
[TBL] [Abstract][Full Text] [Related]
14. The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers.
Shao M; Sun SL; Li MH; Li BX; Yu H; Shen ZY; Ren YC; Hao ZF; Chang ND; Peng HS; Yang BF
J Liposome Res; 2012 Jun; 22(2):168-76. PubMed ID: 22428938
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.
Wang Q; Banerjee K; Vasilinin G; Marier JF; Gibbons JA
J Clin Pharmacol; 2019 May; 59(5):748-762. PubMed ID: 30566230
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals.
Wang Q; Tardi P; Sadowski N; Xie S; Heller D; Mayer L
Nanomedicine; 2020 Nov; 30():102275. PubMed ID: 32750494
[TBL] [Abstract][Full Text] [Related]
17. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.
Mayer LD; Harasym TO; Tardi PG; Harasym NL; Shew CR; Johnstone SA; Ramsay EC; Bally MB; Janoff AS
Mol Cancer Ther; 2006 Jul; 5(7):1854-63. PubMed ID: 16891472
[TBL] [Abstract][Full Text] [Related]
18. Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.
Morris KL; Adams JA; Liu Yin JA
Leuk Res; 2009 Aug; 33(8):1096-9. PubMed ID: 19268363
[TBL] [Abstract][Full Text] [Related]
19. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors.
Forssen EA; Coulter DM; Proffitt RT
Cancer Res; 1992 Jun; 52(12):3255-61. PubMed ID: 1596882
[TBL] [Abstract][Full Text] [Related]
20. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
Zucker D; Barenholz Y
J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
